"Loading Stock Price & Valuation Data ..."
Unlock News Summary by Subscribing to iPick.ai Premium!
Ask anything related to ORKA. [ FAQ on what and how to ask] For non-ORKA questions, click the logo in the upper-right corner to return to the main page and ask there.
CEO:Dr. Lawrence Otto Klein Ph.D.
Headquarter: 855 Oak Grove Avenue, Suite 100, Menlo Park, CA, United States, 94025
Industry: Biotechnology, Investment Track: CRISPR Editing, Employees: 68
Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications. Its lead products include ORKA-001 that targets p19 subunit of interleukin-23, which is in phase 2a trial for the treatment of PsO; and ORKA-002 that targets interleukin-17A and interleukin-17F, which is in phase 2 trial for the treatment of PsO, psoriatic arthritis, and other conditions. The company also develops ORKA-003 for targeting an undisclosed pathway; and ORKA-021, a sequential combination regimen of ORKA-002 and ORKA-001. Oruka Therapeutics, Inc. is headquartered in Menlo Park, California.
My Watchlist
